Gabriel Sanchez-Aldana, MD
Family Medicine · Los Angeles, CANPI 1013025865
Payments from drug & device makers
Across 205 payments — averaging $28.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Johnson & Johnson$864
- Boehringer Ingelheim$864
- AstraZeneca$664
- Novo Nordisk$377
- Lilly USA, LLC$309
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,930100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $1,068 |
| Johnson & Johnson | 34 | $864 |
| Boehringer Ingelheim | 36 | $864 |
| AstraZeneca | 21 | $664 |
| Novo Nordisk | 9 | $377 |
| Lilly USA, LLC | 10 | $309 |
| Novartis | 12 | $264 |
| Daiichi Sankyo Inc. | 5 | $224 |
| Biotronik NRO, Inc. | 3 | $177 |
| Dexcom, Inc. | 2 | $165 |
| Abbott | 1 | $151 |
| Astellas Pharma US Inc | 2 | $151 |
| Exact Sciences | 6 | $120 |
| Octapharma USA, Inc. | 1 | $108 |
| AbbVie | 1 | $101 |
| Amarin Pharma, Inc. | 6 | $86 |
| Verona Pharma, Inc. | 2 | $47 |
| Curonix LLC | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Pfizer | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$221
- FREESTYLE LIBRE 3$151
- XARELTO$131
- DEXCOM G7 GSS (161)$127
- DEXCOM STELO GLUCOSE BIOSENSOR$127
- Enhertu$125
- TRELEGY ELLIPTA$120
- AREXVY$118
- LOKELMA$117
- FIBRYGA$108
- AIRSUPRA$102
- UBRELVY$101
How this compares
$5,930 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 180 | $141,664 |
| TrulicityDulaglutide | 116 | $108,957 |
| OzempicSemaglutide | 83 | $77,301 |
| FarxigaDapagliflozin Propanediol | 77 | $53,013 |
| JanuviaSitagliptin Phosphate | 39 | $27,802 |
| Spiriva RespimatTiotropium Bromide | 47 | $23,611 |
| EliquisApixaban | 32 | $22,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,681 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $15,826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 534 | $15,306 |
| VascepaIcosapent Ethyl | 40 | $14,249 |
| TradjentaLinagliptin | 19 | $13,976 |
| RybelsusSemaglutide | 11 | $13,542 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 60 | $11,330 |
| AmbienZolpidem Tartrate | 13 | $8,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $864 | $179,251246 claims |
| Lilly USA, LLCTrulicity | $309 | $108,957116 claims |
| Novo NordiskOzempic, Rybelsus | $377 | $90,84394 claims |
| AstraZenecaFarxiga, Symbicort | $664 | $57,65699 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,068 | $46,151100 claims |
| PfizerEliquis | $18 | $22,67932 claims |
| Sanofi-aventis U.S. LLCAmbien | $36 | $8,24213 claims |
| NovartisEntresto | $264 | $7,20611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.